Commentary: safety of anti-TNF use in pregnancy

被引：0
|
作者：
Hart, Ailsa [1 ]
机构：
[1] St Marks Hosp, IBD Unit, Harrow, Middx, England
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2020年 / 51卷 / 01期
关键词：
INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB; CONSENSUS;
D O I：
10.1111/apt.15548
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THIS IS A SPECIAL COMMENTARY ON "INTENTIONAL INFLIXIMAB USE DURING PREGNANCY FOR INDUCTION OR MAINTENANCE OF REMISSION IN CROHN'S DISEASE" BY MAHADEVAN, U., KANE, S., SANDBORN, W.J., COHEN, R.D., HANSON, K., TERDIMAN, J.P., AND BINION, D.G., ORIGINALLY PUBLISHED IN AP&T IN 2005. DOI:
引用
收藏
页码：205 / 206
页数：2
相关论文
共 50 条
  • [41] BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
    Ding, Tina
    Ledingham, Jo
    Luqmani, Raashid
    Westlake, Sarah
    Hyrich, Kimme
    Lunt, Mark
    Kiely, Patrick
    Bukhari, Marwan
    Abernethy, Rikki
    Bosworth, Ailsa
    Ostor, Andrew
    Gadsby, Kate
    McKenna, Frank
    Finney, Diana
    Dixey, Josh
    Deighton, Chris
    [J]. RHEUMATOLOGY, 2010, 49 (11) : 2217 - 2219
  • [42] Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review
    Matucci, Andrea
    Cammelli, Daniele
    Cantini, Fabrizio
    Goletti, Delia
    Marino, Valentina
    Milano, Giuseppe Maria
    Scarpa, Raffaele
    Tocci, Giuliano
    Maggi, Enrico
    Vultaggio, Alessandra
    [J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 : 3 - 10
  • [43] Efficacy and safety of anti-TNF agents in patients with enthesitis related arthritis
    P Tynjälä
    V Honkanen
    K Aalto
    T Levälampi
    [J]. Pediatric Rheumatology, 6 (Suppl 1)
  • [44] Safety, efficacy, and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-TNF
    Ben-Horin, S.
    Ungar, B.
    Kopylov, U.
    Lahat, A.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Peled, Y.
    Eliakim, R.
    Del Tedesco, E.
    Paul, S.
    Roblin, X.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S493 - S493
  • [45] SAFETY OF ANTI-TNF AGENTS IN PATIENTS WITH CIRRHOSIS: A CASE CONTROL STUDY
    Kapila, Nikhil
    Gonzalez, Adalberto
    Flocco, Gianina
    Salomon, Fayssa
    Hussain, Ishtiaq
    Melendez-Rosado, Jose
    Castro-Pavia, Fernando J.
    [J]. HEPATOLOGY, 2020, 72 : 726A - 727A
  • [46] SAFETY, EFFICACY AND PHARMACOKINETICS OF VEDOLIZUMAB IN PATIENTS WITH SIMULTANEOUS EXPOSURE TO AN ANTI-TNF
    Ben-Horin, Shomron
    Ungar, Bella
    Kopylov, Uri
    Lahat, Adi
    Yavzori, Miri
    Fudim, Ella
    Picard, Orit
    Eliakim, Abraham R.
    Del Tedesco, Emilie
    Paul, Stephane
    Roblin, Xavier
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S839 - S840
  • [47] Clinical use of anti-TNF therapy and increased risk of infections
    Ali, Tauseef
    Kaitha, Sindhu
    Mahmood, Sultan
    Ftesi, Abdul
    Stone, Jordan
    Bronze, Michael S.
    [J]. DRUG HEALTHCARE AND PATIENT SAFETY, 2013, 5 : 79 - 99
  • [48] Strategic Use of Immunosuppressants and Anti-TNF in Inflammatory Bowel Disease
    Louis, Edouard
    [J]. DIGESTIVE DISEASES, 2013, 31 (02) : 207 - 212
  • [49] Use of anti-TNF drug levels to optimise patient management
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    [J]. FRONTLINE GASTROENTEROLOGY, 2016, 7 (04) : 289 - 300
  • [50] Adverse effects and other issues with the use of anti-TNF therapy
    Rahiman, Mumtaz Abdool
    van der Merwe, Elsabe
    [J]. SA PHARMACEUTICAL JOURNAL, 2008, 75 (09) : 32 - 36
12345